Report Overview

Asia Pacific Next Generation Antibody Market – Industry Trends & Forecast Report, 2030

The Asia Pacific Next Generation Antibody Market size was estimated at USD 1,024.31 million in 2023. During the forecast period between 2024 and 2029, the size of Asia Pacific Next Generation Antibody Market is projected to grow at a CAGR of 12.36% reaching a value of USD 2,061.23 million by 2030. The Asia Pacific Next Generation Antibody Market is propelled by a rising demand for targeted therapies, advancements in biotechnology, and increasing prevalence of chronic diseases. Collaborations between pharmaceutical companies and research institutions, along with growing investments in research and development, contribute to market expansion. Additionally, the region's supportive regulatory environment and a burgeoning biopharmaceutical industry further drive innovations in next generation antibody therapies. The rising adoption of personalized medicine and the quest for more effective and safer treatment options enhance the market growth, positioning the Asia Pacific region as a key player in the development and commercialization of next generation antibodies.

Next Generation Antibody – Overview

Next generation antibodies represent an advanced class of therapeutic proteins designed to enhance traditional antibody capabilities. Engineered for improved target specificity, binding affinity, and reduced side effects, they often incorporate novel formats such as bispecific or multi-specific antibodies. Additionally, advancements in technologies like phage display, transgenic animals, and computational modeling contribute to their development. The antibodies hold significant promise in treating various diseases, including cancer and autoimmune disorders, offering more precise and potent therapeutic options compared to conventional antibodies. The innovative design aims to address challenges and enhance therapeutic efficacy in diverse medical applications.

Asia Pacific Next Generation Antibody Market  

Growth Drivers

Escalating Incidence of Chronic Diseases

In an era marked by a rising prevalence of chronic diseases across the Asia Pacific region, the Next Generation Antibody Market is experiencing unprecedented growth. The surge is attributed to the pressing need for advanced therapeutic solutions, propelling the market to new heights. As the healthcare landscape evolves to combat complex diseases, the demand for innovative antibody therapies continues to skyrocket, positioning the Asia Pacific market as a pivotal player in the global biopharmaceutical landscape.

Challenges

Innovative Solutions Needed to Address Soaring Expenses

The Asia Pacific Next Generation Antibody Market grapples with the formidable challenge of high costs linked to development and manufacturing. The financial burden, encompassing research, clinical trials, and production expenses, poses a significant barrier to market growth. Stakeholders must explore creative and cost-effective strategies to navigate the restraint, fostering collaborations, leveraging technology, and implementing efficient production methods to propel the market forward in the face of financial challenges.

Impact of Escalating Geopolitical Tensions on Asia Pacific Next Generation Antibody Market  

The Asia Pacific Next Generation Antibody Market is significantly influenced by escalating geopolitical tensions, particularly involving major players such as China, the United States, and neighboring nations. This complex geopolitical dynamic creates a ripple effect on the antibody market, impacting trade restrictions, export controls, and international relations. The resulting disruptions in the supply chain for next generation antibody-related products, coupled with regulatory hurdles and political uncertainties, pose challenges to collaborative research efforts and hinder the flow of crucial information for innovation in antibody development. Geopolitical tensions may also prompt shifts in research and development investments, leading to disparities in technological advancements and market growth among nations in the region. Additionally, the tensions could affect the regulatory environment, potentially altering approval processes for next generation antibody therapies and requiring companies to adapt their strategic plans. The market's overall progress is intricately linked to geopolitical realities, and any escalation in tensions has the potential to reshape the landscape significantly.

Asia Pacific Next Generation Antibody Market  

Segmental Coverage

Asia Pacific Next Generation Antibody Market – By Therapeutic Area

Based on therapeutic area, Asia Pacific Next Generation Antibody Market is divided into Oncology and Autoimmune/Inflammatory segments. The oncology segment is a larger therapeutic area in the market. Both oncology and autoimmune/inflammatory segments represent critical areas in the region's healthcare landscape, reflecting the demand for advanced antibody therapies to address diverse medical challenges. The market's focus on oncology highlights a commitment to advancing cancer treatment, while the autoimmune/inflammatory segment underscores the importance of addressing conditions related to the immune system. Together, the segments signify the growing significance of next generation antibody solutions in tackling major health concerns across the Asia Pacific region

Asia Pacific Next Generation Antibody Market – By Technology

Based on technology, Asia Pacific Next Generation Antibody Market is divided into Antibody-Drug Conjugates (ADCs), Bispecific Antibodies, FC Engineered Antibodies, Antibody Fragments & Antibody-like Proteins, and Biosimilar Antibody product segments. The antibody-drug conjugates (ADCs) segment is the largest technology in the Asia Pacific Next Generation Antibody Market. The innovative segment combines monoclonal antibodies with cytotoxic drugs, targeting specific cancer cells while minimizing damage to healthy cells. ADCs represent a significant advancement in cancer treatment, contributing to the market's growth. Other segments, such as bispecific antibodies, FC-engineered antibodies, antibody fragments, antibody-like proteins, and biosimilar antibody products, also play crucial roles in shaping the market landscape and addressing diverse therapeutic needs. However, ADCs stand out as the dominant and impactful segment in the dynamic landscape of next generation antibody development in the Asia Pacific region.

Asia Pacific Next Generation Antibody Market – By Country

Based on country, Asia Pacific Next Generation Antibody Market is divided into China, India, Japan, South Korea, Indonesia, Vietnam, Malaysia, and Rest of Asia Pacific. China holds the largest market share, exhibiting substantial growth in the next generation antibody market. The country's increasing investments in research and development, coupled with a growing demand for advanced therapeutic antibodies, contribute significantly to its dominant position in the regional market. This underscores China's pivotal role in shaping the future landscape of next generation antibody advancements in the Asia Pacific region.

Competitive Landscape

Major players in the Asia Pacific Next Generation Antibody Market include F. Hoffmann-La Roche Ltd, Kyowa Kirin Co., Ltd, Seagen Inc., ImmunoGen, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., and Pfizer Inc. These companies use various strategies, including increasing investments in their R&D activities, mergers and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in the Asia Pacific Next Generation Antibody Market.

Recent Developments

• In July 2021 - Roche announced that Japan's Ministry of Health, Labour and Welfare (MHLW) had approved Ronapreve (casirivimab and imdevimab) to treat patients with mild to moderate COVID-19 via intravenous infusion.

• In December 2020 - CEPI, the Coalition for Epidemic Preparedness Innovations, announced a collaboration with South Korea-based SK Bioscience to advance the development of a next generation vaccine against SARS-CoV-2, the virus that causes COVID-19.

Scope of Report

By Therapeutic Area

• Oncology

• Autoimmune/Inflammatory

By Technology

• Antibody-Drug Conjugates (ADC's)

• Bispecific Antibodies

• FC Engineered Antibodies

• Antibody Fragments & Antibody-like Proteins

• Biosimilar Antibody Products

By Country

• China

• India

• Japan

• South Korea

• Indonesia

• Vietnam

• Malaysia

• Rest of Asia Pacific

1. Research Framework
   1. Research Objective
   2. Product Overview
   3. Market Segmentation
2. Executive Summary
3. Asia Pacific Next Generation Antibody Market Insights
   1. Industry Value Chain Analysis
      1. DROC Analysis
      2. Growth Drivers
         1. The rising prevalence of chronic diseases
         2. Increasing investment in antibody research and development
      3. Restraints
         1. High costs associated with development and manufacturing
      4.  Opportunities
         1. Advancement in technology
      5. Challenges
         1. Complex regulatory environment
   2. Technological Advancements/Recent Developments
   3. Regulatory Framework
   4. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
4. Asia Pacific Next Generation Antibody Market Overview
   1. Market Size & Forecast, 2019–2030
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Therapeutic Area
         1. Oncology
         2. Autoimmune/Inflammatory
      2. By Technology
         1. Antibody-Drug Conjugates (ADC's)
         2. Bispecific Antibodies
         3. FC Engineered Antibodies
         4. Antibody Fragments and Antibody-like Proteins
         5. Biosimilar Antibody Products
      3. By Country
         1. China
         2. India
         3. Japan
         4. South Korea
         5. Indonesia
         6. Vietnam
         7. Malaysia
         8. Rest of Asia Pacific
5. China Next Generation Antibody Market
   1. Market Size & Forecast, 2019–2030
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Therapeutic Area
      2. By Technology
6. India Next Generation Antibody Market
   1. Market Size & Forecast, 2019–2030
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Therapeutic Area
      2. By Technology
7. Japan Next Generation Antibody Market
   1. Market Size & Forecast, 2019–2030
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Therapeutic Area
      2. By Technology
8. South Korea Next Generation Antibody Market
   1. Market Size & Forecast, 2019–2030
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Therapeutic Area
      2. By Technology
9. Indonesia Next Generation Antibody Market
   1. Market Size & Forecast, 2019–2030
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Therapeutic Area
      2. By Technology
10. Vietnam Next Generation Antibody Market
    1. Market Size & Forecast, 2019–2030
       1. By Value (USD Million)
    2. Market Share & Forecast
       1. By Therapeutic Area
       2. By Technology
11. Malaysia Next Generation Antibody Market
    1. Market Size & Forecast, 2019–2030
       1. By Value (USD Million)
    2. Market Share & Forecast
       1. By Therapeutic Area
       2. By Technology
12. Rest of Asia Pacific Next Generation Antibody Market
    1. Market Size & Forecast, 2019–2030
       1. By Value (USD Million)
    2. Market Share & Forecast
       1. By Therapeutic Area
       2. By Technology
13. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. Asia Pacific Next Generation Antibody Company Market Share Analysis, 2023
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
14. Impact of Escalating Geopolitical Tensions on Asia Pacific Next Generation Antibody Market
15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)
    1. F. Hoffmann-La Roche Ltd
    2. Kyowa Kirin Co., Ltd
    3. Seagen Inc.
    4. ImmunoGen, Inc.
    5. Takeda Pharmaceutical Company Limited
    6. Amgen Inc.
    7. Pfizer Inc.
    8. Other Prominent Players
16. Key Strategic Recommendations
17. Research Methodology
    1.  Qualitative Research
       1.  Primary & Secondary Research
    2.  Quantitative Research
    3.  Market Breakdown & Data Triangulation
       1.  Secondary Research
       2.  Primary Research
    4.  Breakdown of Primary Research Respondents, By Region
    5.  Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

List of Figures

Figure 1       Asia Pacific Next Generation Antibody Segmentation        

Figure 2       Asia Pacific Next Generation Antibody Market Value Chain Analysis      

Figure 3       Company Market Share Analysis, 2023

Figure 4       Asia Pacific Next Generation Antibody Market Size, By Value (USD Million), 2019–2030 

Figure 5       Asia Pacific Next Generation Antibody Market Share, By Therapeutic Area, By Value, 2019–2030

Figure 6       Asia Pacific Next Generation Antibody Market Share, By Technology, By Value, 2019–2030 

Figure 7       Asia Pacific Next Generation Antibody Market Share, By Country, By Value, 2019–2030 

Figure 8       China Next Generation Antibody Market Size, By Value (USD Million), 2019–2030         

Figure 9       China Next Generation Antibody Market Share, By Therapeutic Area, By Value, 2019–2030 

Figure 10     China Next Generation Antibody Market Share, By Technology, By Value, 2019–2030 

Figure 11     India Next Generation Antibody Market Size, By Value (USD Million), 2019–2030         

Figure 12     India Next Generation Antibody Market Share, By Therapeutic Area, By Value, 2019–2030 

Figure 13     India Next Generation Antibody Market Share, By Technology, By Value, 2019–2030 

Figure 14     Japan Next Generation Antibody Market Size, By Value (USD Million), 2019–2030         

Figure 15     Japan Next Generation Antibody Market Share, By Therapeutic Area, By Value, 2019–2030 

Figure 16     Japan Next Generation Antibody Market Share, By Technology, By Value, 2019–2030 

Figure 17     South Korea Next Generation Antibody Market Size, By Value (USD Million), 2019–2030 

Figure 18     South Korea Next Generation Antibody Market Share, By Therapeutic Area, By Value, 2019–2030

Figure 19     South Korea Next Generation Antibody Market Share, By Technology, By Value, 2019–2030 

Figure 20     Australia & New Zealand Next Generation Antibody Market Size, By Value (USD Million), 2019–2030       

Figure 21     Australia & New Zealand Next Generation Antibody Market Share, By Therapeutic Area, By Value, 2019–2030      

Figure 22     Australia & New Zealand Next Generation Antibody Market Share, By Technology, By Value, 2019–2030     

Figure 23     Indonesia Next Generation Antibody Market Size, By Value (USD Million), 2019–2030 

Figure 24     Indonesia Next Generation Antibody Market Share, By Therapeutic Area, By Value, 2019–2030

Figure 25     Indonesia Next Generation Antibody Market Share, By Technology, By Value, 2019–2030 

Figure 26     Malaysia Next Generation Antibody Market Size, By Value (USD Million), 2019–2030 

Figure 27     Malaysia Next Generation Antibody Market Share, By Therapeutic Area, By Value, 2019–2030 

Figure 28     Malaysia Next Generation Antibody Market Share, By Technology, By Value, 2019–2030 

Figure 29     Singapore Next Generation Antibody Market Size, By Value (USD Million), 2019–2030 

Figure 30     Singapore Next Generation Antibody Market Share, By Therapeutic Area, By Value, 2019–2030

Figure 31     Singapore Next Generation Antibody Market Share, By Technology, By Value, 2019–2030 

Figure 32     Vietnam Next Generation Antibody Market Size, By Value (USD Million), 2019–2030 

Figure 33     Vietnam Next Generation Antibody Market Share, By Therapeutic Area, By Value, 2019–2030 

Figure 34     Vietnam Next Generation Antibody Market Share, By Technology, By Value, 2019–2030 

Figure 35     Rest of APAC Next Generation Antibody Market Size, By Value (USD Million), 2019–2030 

Figure 36     Rest of APAC Next Generation Antibody Market Share, By Therapeutic Area, By Value, 2019–2030

Figure 37     Rest of APAC Next Generation Antibody Market Share, By Technology, By Value, 2019–2030 

List of Tables

Table 1        Asia Pacific Next Generation Antibody Market Size, By Value (USD Million), 2019–2030

Table 2        Asia Pacific Next Generation Antibody Market Size, By Therapeutic Area, By Value, 2019–2030

Table 3        Asia Pacific Next Generation Antibody Market Size, By Technology, By Value, 2019–2030

Table 4        Asia Pacific Next Generation Antibody Market Size, By Country, By Value, 2019–2030

Table 5        China Next Generation Antibody Market Size, By Value (USD Million), 2019–2030

Table 6        China Next Generation Antibody Market Size, By Therapeutic Area, By Value, 2019–2030

Table 7        China Next Generation Antibody Market Size, By Technology, By Value, 2019–2030

Table 8        India Next Generation Antibody Market Size, By Value (USD Million), 2019–2030

Table 9        India Next Generation Antibody Market Size, By Therapeutic Area, By Value, 2019–2030

Table 10      India Next Generation Antibody Market Size, By Technology, By Value, 2019–2030

Table 11      Japan Next Generation Antibody Market Size, By Value (USD Million), 2019–2030

Table 12      Japan Next Generation Antibody Market Size, By Therapeutic Area, By Value, 2019–2030

Table 13      Japan Next Generation Antibody Market Size, By Technology, By Value, 2019–2030

Table 14      South Korea Next Generation Antibody Market Size, By Value (USD Million), 2019–2030

Table 15      South Korea Next Generation Antibody Market Size, By Therapeutic Area, By Value, 2019–2030

Table 16      South Korea Next Generation Antibody Market Size, By Technology, By Value, 2019–2030

Table 17      Australia & New Zealand Next Generation Antibody Market Size, By Value (USD Million), 2019–2030

Table 18      Australia & New Zealand Next Generation Antibody Market Size, By Therapeutic Area, By Value, 2019–2030

Table 19      Australia & New Zealand Next Generation Antibody Market Size, By Technology, By Value, 2019–2030

Table 20      Indonesia Next Generation Antibody Market Size, By Value (USD Million), 2019–2030

Table 21      Indonesia Next Generation Antibody Market Size, By Therapeutic Area, By Value, 2019–2030

Table 22      Indonesia Next Generation Antibody Market Size, By Technology, By Value, 2019–2030

Table 23      Malaysia Next Generation Antibody Market Size, By Value (USD Million), 2019–2030

Table 24      Malaysia Next Generation Antibody Market Size, By Therapeutic Area, By Value, 2019–2030

Table 25      Malaysia Next Generation Antibody Market Size, By Technology, By Value, 2019–2030

Table 26      Singapore Next Generation Antibody Market Size, By Value (USD Million), 2019–2030

Table 27      Singapore Next Generation Antibody Market Size, By Therapeutic Area, By Value, 2019–2030

Table 28      Singapore Next Generation Antibody Market Size, By Technology, By Value, 2019–2030

Table 29      Vietnam Next Generation Antibody Market Size, By Value (USD Million), 2019–2030

Table 30      Vietnam Next Generation Antibody Market Size, By Therapeutic Area, By Value, 2019–2030

Table 31      Vietnam Next Generation Antibody Market Size, By Technology, By Value, 2019–2030

Table 32      Rest of APAC Next Generation Antibody Market Size, By Value (USD Million), 2019–2030

Table 33      Rest of APAC Next Generation Antibody Market Size, By Therapeutic Area, By Value, 2019–2030

Table 34      Rest of APAC Next Generation Antibody Market Size, By Technology, By Value, 2019–2030

Table 35      F. Hoffmann-La Roche Ltd Generation Company Overview

Table 36      F. Hoffmann-La Roche Ltd Generation Financial Overview

Table 37      Kyowa Kirin Co., Ltd Company Overview

Table 38      Kyowa Kirin Co., Ltd Financial Overview

Table 39      Seagen Inc. Company Overview

Table 40      Seagen Inc. Financial Overview

Table 41      ImmunoGen, Inc. Company Overview

Table 42      ImmunoGen, Inc. Financial Overview

Table 43      Takeda Pharmaceutical Company Limited Company Overview

Table 44      Takeda Pharmaceutical Company Limited Financial Overview

Table 45      Amgen Inc. Company Overview

Table 46      Amgen Inc. Financial Overview

Table 47      Pfizer Inc. Company Overview

Table 48      Pfizer Inc. Financial Overview